- Home
- IHT vs MTVA Comparison
IHT vs MTVA Comparison
Compare IHT & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHT
- MTVA
- Stock Information
- Founded
- IHT 1971
- MTVA 2014
- Country
- IHT United States
- MTVA United States
- Employees
- IHT N/A
- MTVA N/A
- Industry
- IHT Investment Bankers/Brokers/Service
- MTVA
- Sector
- IHT Finance
- MTVA
- Exchange
- IHT Nasdaq
- MTVA NYSE
- Market Cap
- IHT 18.0M
- MTVA 18.9M
- IPO Year
- IHT N/A
- MTVA N/A
- Fundamental
- Price
- IHT $2.18
- MTVA $1.85
- Analyst Decision
- IHT
- MTVA
- Analyst Count
- IHT 0
- MTVA 0
- Target Price
- IHT N/A
- MTVA N/A
- AVG Volume (30 Days)
- IHT 2.6K
- MTVA 256.5K
- Earning Date
- IHT 12-31-2024
- MTVA 11-07-2024
- Dividend Yield
- IHT 0.89%
- MTVA N/A
- EPS Growth
- IHT N/A
- MTVA N/A
- EPS
- IHT N/A
- MTVA N/A
- Revenue
- IHT $7,692,305.00
- MTVA N/A
- Revenue This Year
- IHT N/A
- MTVA N/A
- Revenue Next Year
- IHT N/A
- MTVA N/A
- P/E Ratio
- IHT N/A
- MTVA N/A
- Revenue Growth
- IHT 6.27
- MTVA N/A
- 52 Week Low
- IHT $1.22
- MTVA $1.55
- 52 Week High
- IHT $2.36
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- IHT 60.62
- MTVA N/A
- Support Level
- IHT $1.95
- MTVA N/A
- Resistance Level
- IHT $2.24
- MTVA N/A
- Average True Range (ATR)
- IHT 0.13
- MTVA 0.00
- MACD
- IHT -0.00
- MTVA 0.00
- Stochastic Oscillator
- IHT 88.39
- MTVA 0.00
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.